GT Biopharma, Inc.GTBPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank72
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P72
Within normal range
vs 2Y Ago
17.8x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 53.53% |
| Q3 2025 | 138.96% |
| Q2 2025 | 38.06% |
| Q1 2025 | -54.56% |
| Q4 2024 | -20.20% |
| Q3 2024 | 8.25% |
| Q2 2024 | -8.30% |
| Q1 2024 | 27.77% |
| Q4 2023 | 3.01% |
| Q3 2023 | 15.20% |
| Q2 2023 | -24.27% |
| Q1 2023 | -31.37% |
| Q4 2022 | -31.40% |
| Q3 2022 | 128.27% |
| Q2 2022 | -44.11% |
| Q1 2022 | -71.74% |
| Q4 2021 | 140.07% |
| Q3 2021 | 32.18% |
| Q2 2021 | -86.32% |
| Q1 2021 | 1297.45% |
| Q4 2020 | -3.50% |
| Q3 2020 | 31.24% |
| Q2 2020 | 107.24% |
| Q1 2020 | -13.05% |
| Q4 2019 | -76.07% |
| Q3 2019 | 68.71% |
| Q2 2019 | -34.05% |
| Q1 2019 | 73.32% |
| Q4 2018 | -63.08% |
| Q3 2018 | 164.17% |
| Q2 2018 | -48.30% |
| Q1 2018 | -35.70% |
| Q4 2017 | -95.46% |
| Q3 2017 | 12000.57% |
| Q2 2017 | -25.11% |
| Q1 2017 | 143.71% |
| Q4 2016 | -74.91% |
| Q3 2016 | 21.86% |
| Q2 2016 | -49.10% |
| Q1 2016 | 54.26% |